Understand Roles of Remdesivir and Dexamethasone for COVID-19

December 2020

Remdesivir (Veklury) is now FDA-approved for all hospitalized COVID-19 patients who are at least 12 years old and weigh 40 kg or more.

But this doesn’t mean it should be used more. And conflicting guidelines add to the confusion.

Be prepared to explain remdesivir’s current role...especially compared to dexamethasone.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote